Cost-Effectiveness of Gliclazide-Based Intensive Glucose Control vs. Standard Glucose Control in Type 2 Diabetes Mellitus. An Economic Analysis of the ADVANCE Trial in Vietnam.

Frontiers in Public Health
Hai-Yen Nguyen-ThiOlivier Ethgen

Abstract

Introduction: ADVANCE was a large, multinational clinical study conducted over 5 years in type 2 diabetes mellitus (T2DM). In all, 11,140 patients were randomly assigned to receive gliclazide-based intensive glucose control (IGC) or standard glucose control (SGC). IGC was shown to significantly reduce the incidence of major macrovascular and microvascular events (composite endpoint) or major microvascular events compared with SGC, primarily by enhancing renal protection. We assessed the cost-effectiveness of IGC vs. SGC, based on the ADVANCE results, from a Vietnamese healthcare payer perspective. Materials and Methods: A partitioned survival times model across five health states (no complications, myocardial infarction, stroke, end-stage renal disease [ESRD], and diabetes-related eye-disease) was designed. Time-to-event curves were informed by the cumulative incidence of events and corresponding hazard ratios from the ADVANCE study. Health outcomes were expressed in terms of ESRD avoided and quality-adjusted life years (QALYs). Costs (in US $) comprised treatment costs and health state costs. Utility weights and costs were documented from literature reporting Vietnamese estimates. For sensitivity analyses, all parameters were ...Continue Reading

References

Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Nov 13, 2009·Diabetes Care·Simon R Heller, UNKNOWN ADVANCE Collaborative Group
Jan 11, 2013·Physiological Reviews·Josephine M Forbes, Mark E Cooper
Sep 23, 2014·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE-ON Collaborative Group
Sep 23, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Phil McEwanDavid Grant
Apr 18, 2015·Bulletin of the World Health Organization·Elliot MarseilleSydney Rosen
Jul 19, 2015·Asia-Pacific Journal of Public Health·Chung T NguyenColin W Binns
Mar 24, 2016·Diabetes Care·Muh Geot WongUNKNOWN ADVANCE-ON Collaborative Group
Oct 30, 2016·Clinical Epidemiology·Diana Hedevang ChristensenReimar Wernich Thomsen
Apr 4, 2017·The Lancet. Diabetes & Endocrinology·Sophia ZoungasUNKNOWN Collaborators on Trials of Lowering Glucose (CONTROL) group
May 21, 2017·The American Journal of Medicine·James Thrasher
Sep 19, 2017·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Nguyen Tu Dang LeTrung Quang Vo
Oct 13, 2017·Health and Quality of Life Outcomes·Long Hoang NguyenCarl A Latkin
Dec 9, 2017·Nature Reviews. Endocrinology·Yan ZhengFrank B Hu
May 15, 2018·BMJ Open Diabetes Research & Care·Raju P SapkotaShahina Pardhan
Nov 25, 2018·Diabetes, Obesity & Metabolism·Ruth L M Cordiner, Ewan R Pearson
Feb 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Viswanathan MohanKamlesh Khunti
Feb 21, 2019·Critical Care Clinics·Renata Libianto, Elif I Ekinci
Nov 28, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Viswanathan MohanJean C Mbanya
Jul 21, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Aus AlzaidPetar Atanasov

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies

Software Mentioned

ADVANCE

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.